Community oncology practice
Appears in 1 story
Led U.S. community-based enrollment for the Krascendo 1 trial
Five years after the first KRAS inhibitor reached the market, a next-generation drug just beat the existing ones head-to-head. The Phase III Krascendo 1 trial found divarasib cut the risk of death by 44% and nearly doubled response rates in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
